Insulet Corporation (PODD)
| Market Cap | 17.36B |
| Revenue (ttm) | 2.71B |
| Net Income (ttm) | 247.10M |
| Shares Out | 70.40M |
| EPS (ttm) | 3.48 |
| PE Ratio | 70.88 |
| Forward PE | 38.86 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 983,721 |
| Open | 248.62 |
| Previous Close | 251.50 |
| Day's Range | 245.66 - 252.63 |
| 52-Week Range | 230.05 - 354.88 |
| Beta | 1.42 |
| Analysts | Strong Buy |
| Price Target | 358.00 (+45.17%) |
| Earnings Date | Feb 18, 2026 |
About PODD
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controll... [Read more]
Financial Performance
In 2025, Insulet's revenue was $2.71 billion, an increase of 30.73% compared to the previous year's $2.07 billion. Earnings were $247.10 million, a decrease of -40.93%.
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for PODD stock is "Strong Buy." The 12-month stock price target is $358.0, which is an increase of 45.17% from the latest price.
News
Insulet: The Growth Doesn't Stop Here
The market is overstating the impact of GLP-1s and fails to recognize that GLP-1s pose no direct threat to Insulet's customer base. International expansion into Europe (the largest addressable market ...
Insulet Q4 Earnings Review: Strong Performance Meets Sky-High Expectations
Insulet Q4 Earnings Review: Strong Performance Meets Sky-High Expectations
Insulet Corporation (PODD) Q4 2025 Earnings Call Transcript
Insulet Corporation (PODD) Q4 2025 Earnings Call Transcript
Diabetes-Focused Insulet Forecasts Strong 2026 Growth, Stock Soars
Insulet Corporation (NASDAQ: PODD) stock is trading higher on Wednesday after the company reported better-than-expected fourth-quarter earnings and 2026 guidance.
Insulet beats quarterly estimates on strong demand for wearable insulin pumps
Insulet reported better-than-expected fourth-quarter results on Wednesday, on the back of strong demand for its tubeless insulin pumps that eliminate the need for daily injections.
Insulet Reports Fourth Quarter and Full Year 2025 Results
ACTON, Mass.--(BUSINESS WIRE)--Insulet Reports Fourth Quarter and Full Year 2025 Results.
Insulet Launches Omnipod® 5 and Omnipod Discover™ in the Middle East to Transform Diabetes Care
ACTON, Mass.--(BUSINESS WIRE)--Insulet Launches Omnipod® 5 and Omnipod Discover™ in the Middle East to Transform Diabetes Care.
Is PODD A Better Bet Than ISRG Stock?
PODD is Intuitive Surgical's counterpart in the Health Care Equipment sector that has:
Insulet Corporation (PODD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Insulet Corporation (PODD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Insulet to Announce Fourth Quarter and Full Year 2025 Financial Results on February 18, 2026
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced i...
Insulet Redefines Diabetes at CES with "Liveable Technology" — A New Frontier in Human-Centered Connected Health
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced i...
Insulet to Participate in 44th Annual J.P. Morgan Healthcare Conference
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will prese...
Insulet Expands Omnipod® U.S. Recycling Program, Diverting Millions of Pods from Landfills and Creating a More Sustainable Future
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod brand of products, has announced ...
Eight stock picks to play one of the healthiest corners of the market
The healthcare sector of the U.S. stock market as a whole is cheaply priced, which can make it attractive to investors concerned that the S&P 500 has gotten too expensive several years into a bull mar...
Insulet Announces FDA 510(k) Clearance of Omnipod® 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced i...
Artisan International Small-Mid Fund Q3 2025 Contrarianism Pays Off
Our philosophy often runs counter to prevailing market sentiment, especially in times of excessive concentration and narrow market leadership. During this time, when many investors saw insulin pumps a...
Insulet Corporation (PODD) Analyst/Investor Day Transcript
Insulet Corporation ( PODD) Analyst/Investor Day November 20, 2025 9:00 AM EST Company Participants Clare Trachtman - Vice President of Investor Relations Ashley McEvoy - CEO, President & Director Er...
Insulet Outlines Long-Term Strategy to Drive Growth and Value Creation at 2025 Investor Day
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today hosted ...
PODD Vs. Intuitive Surgical: This Underdog Might Just Win
When it comes to surgical innovation, Intuitive Surgical (NASDAQ: ISRG) often dominates investor attention. But Insulet Corporation (NASDAQ: PODD), best known for its Omnipod insulin delivery system, ...
Insulet Corporation (PODD) Q3 2025 Earnings Call Transcript
Insulet Corporation ( PODD) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Clare Trachtman - Vice President of Investor Relations Ashley McEvoy - CEO, President & Director Fl...
Insulet tops quarterly estimates on demand for wearable insulin pumps
Medical device maker Insulet on Thursday posted third-quarter results that surpassed Wall Street's expectations on strong demand for its wearable insulin pumps, which eliminate the need for daily inje...
Insulet Reports Third Quarter 2025 Results
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced i...
Final Trades: Insulet Corp, Uber and Apollo Global
The Investment Committee give you their top stocks to watch for the second half.
Insulet Champions Workplace Inclusion for People with Diabetes with New Data and Tools Released for Diabetes Awareness Month
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced i...
